Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma

Background. The modern therapies of advanced melanoma include targeted medicines for patients with BRAF mutations. Nowadays, a new perspective on immuno-oncologic medicine pembolizumab became available in Russia. Objective. Assessment of the clinical and economic effectiveness of the use of pembolizumab in the treatment of unrespectable and metastatic melanoma in comparison with targeted medicines in the context of Russian public health. Materials and methods. The Markov model was developed, including the states «without progression», «after progression» and «death», the duration of one Markov cycle is 1 month, the modeling time horizon is 5 years. The probabilities of transitions between states were described using mathematical formulas obtained as a result of digitization and approximation of Kaplan-Mayer survival curves, which were derived from randomized clinical trials KEYNOTE-006, COMBI-v and COMBI-d. Direct medical costs (including drug costs, treatment of adverse events, second-line therapy after disease progression, and palliative care) were analyzed. We did not take into account the costs associated with laboratory-diagnostic procedures and visits to the doctor. The sources of information were: weighted average prices of medicines indicated during public procurement for 2016 (the price of the drug pembolizumab provided by the manufacturer), a program of state guarantees for providing free medical care to Russian citizens for 2016, federal coefficients of relative costs for clinical and statistical groups. The effectiveness criterion for cost-effectiveness analysis was the average number of saved months of a patient’s life. Results. The average number of months saved was 30, 23, 24 and 30 months with pembolizumab, vemurafenib, dabrafenib and dabrafenib plus tramethanib, respectively (calculated using the developed model). Thus, pembolizumab has the same effectiveness as a combination of dabrafenib + tramethanib and is more effective than monotherapy with targeted drugs (dabrafenib or vemurafenib). Direct medical costs per patient over 5 years were approximately 4.06, 5.53, 5.91 and 15.72 million rubles when using pembolizumab, dabrafenib, vemurafenib and a combination of dabrafenib + trametinib, respectively. The health budget saving with pembolizumab instead of dabrafenib, vemurafenib and dabrafenib + trametinib combination may be 26%, 31% and 74%, respectively. Conclusion. Pembolizumab is a rational and economically justified choice for the treatment of unresectable and metastatic melanoma since it leads to cost savings when overall survival is increased.

пембролизумаб, клинико-экономический анализ, фармакоэкономическое исследование, вемурафениб, дабрафениб, онкоиммунология, таргетная терапия, метастатическая меланома, pembrolizumab, cost-effectiveness, health economics, vemurafenib, dabrafenib, oncoimmunology, targeted therapy, advanced melanoma

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology TM Melanoma V2.2013.

2. Finn L. et al. Therapy for metastatic melanoma: the past, present, and future. BMCMedicine 2012; 10:23.

3. Румянцев А.А., Тюляндин С.А. Эффективность ингибиторов Контрольных точек иммунного ответа в лечении солидных опухолей. Практическая онкология 2016; 17: 2: 74-89.

4. Колбин А.С., Курылев А.А., Вилюм И.А. Фармакоэкономический анализ применения вемурафениба для лечения неоперабельной или метастатической меланомы у пациентов с мутацией BRAF ?600. Фармакоэкономика: теория и практика. 2015; 3: 4: 15-27.

5. Куликов А.Ю., Почуприна А.А. Фармакоэкономическая оценка применения лекарственного препарата дабрафениб у пациентов с нерезектабельной и метастатической меланомой кожи с мутацией гена BRAF V600. Фармакоэкономика: Теория и практика. 2016; 4: 1: 102-108.

6. Куликов А.Ю., Скрипник А.Р. Анализ «влияния на бюджет» применения лекарственного препарата ипилимумаб у пациентов с метастатической меланомой кожи. Фармакоэкономика: теория и практика. 2016; 4: 3: 69-73.

7. Программа государственных гарантий бесплатного оказания гражданам медицинской помощи на 2016 год (утв. постановлением Правительства РФ от 19 декабря 2015 г. №1382).

8. Методические рекомендации по способам оплаты медицинской помощи за счет средств обязательного медицинского страхования - письмо от 24.12.2015 Министерства здравоохранения Российской Федерации N 11-9/10/2-7938 и Федерального фонда обязательного медицинского страхования N 8089/21-и.

9. Колбин А.С., Вилюм И.А., Проскурин М.А, Балыкина Ю.Е. Фармакоэкономический анализ применения ибрутиниба в первой линии терапии хронического лимфолейкоза у пациентов с делецией 17р. Качественная клиническая практика. 2015; 1: 32-43.

10. Robert C., Schachter J., Long G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521-32.

11. Robert C., Karaszewska B., Schachter J., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015; 372 (1): 30-39.

12. Long G.V., Stroyakovskiy D., Gogas H., et al. Dabrafenib and trametinib vs dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, doubleblind, phase 3 randomised controlled trial. Lancet. 2015; 386 (9992): 444-451.

13. McArthur GAC, Chapman P.B., Robert C., et al. Safety and efficacy of vemurafenib inBRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. LancetOncol. 2014; 15 (3): 323-332.

14. Abdel-Rahman O. Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. Immunotherapy. 2016 Dec; 8 (12): 1383-1391.

15. Robert C., Ribas A., Wolchok J.D. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384 (9948): 1109-17.